fishing gear Je'Shawn Stevenson scores 23 to lead Cleveland State over Midway University 116-60Biden touts economic legacy, says Trump will inherit a strong economy

India News | Gurugram Cyber Cops Nab Man from TN for Running Illegal SIM Card Racket

SOUTH SAN FRANCISCO, Calif., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on November 29, 2024 it granted stock options to purchase an aggregate of 34,515 shares of common stock and 22,410 restricted stock units (RSUs) that will be settled into shares of common stock upon vesting to 7 employees, whose employment commenced in November 2024, as a material inducement to their employment. The RSUs will vest over 3 years, with 40% of the RSUs vesting on the first anniversary of the applicable grant date, an additional 40% of the RSUs vesting on the second anniversary of the grant date and the final 20% vesting on the third anniversary of the grant date, in each case, subject to each respective employee’s continued service with the Company. The stock options that were granted are subject to an exercise price of $51.86 per share, which is equal to the closing price of the Company’s common stock on November 29, 2024, and will vest over 4 years, with 1/4th of the shares underlying the employee’s option vesting on the one-year anniversary of the grant date and the remaining shares thereafter vesting in monthly installments at a rate of 1/48th of the shares underlying such stock options over the subsequent 36 months, subject to each respective employee’s continued service with the Company. The stock options have a 10-year term. These awards are subject to the terms and conditions of the Company's Amended and Restated 2004 Equity Incentive Plan and the applicable award agreements pursuant to which the awards were granted. The stock options and RSUs were granted as material inducements to employment in accordance with Nasdaq Listing Rule 5635(c)(4). About Cytokinetics Cytokinetics is a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing and commercializing muscle biology-directed drug candidates as potential treatments for debilitating diseases in which cardiac muscle performance is compromised. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to impact myocardial muscle function and contractility. Following positive results from SEQUOIA-HCM, the pivotal Phase 3 clinical trial evaluating aficamten, a next-in-class cardiac myosin inhibitor, in obstructive hypertrophic cardiomyopathy (HCM), Cytokinetics is progressing regulatory submissions for aficamten for the treatment of obstructive HCM in the US, Europe, and China. Aficamten is also currently being evaluated in MAPLE-HCM, a Phase 3 clinical trial of aficamten as monotherapy compared to metoprolol as monotherapy in patients with obstructive HCM, ACACIA-HCM, a Phase 3 clinical trial of aficamten in patients with non-obstructive HCM, CEDAR-HCM, a clinical trial of aficamten in a pediatric population with obstructive HCM, and FOREST-HCM, an open-label extension clinical study of aficamten in patients with HCM. Cytokinetics is also developing omecamtiv mecarbil , a cardiac muscle activator, in patients with heart failure with severely reduced ejection fraction (HFrEF), CK-586, a cardiac myosin inhibitor with a mechanism of action distinct from aficamten for the potential treatment of heart failure with preserved ejection fraction (HFpEF), and CK-089, a fast skeletal muscle troponin activator (FSTA) for the potential treatment of a specific type of muscular dystrophy. For additional information about Cytokinetics, visit www.cytokinetics.com and follow us on X , LinkedIn , Facebook and YouTube . Forward-Looking Statements This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act's Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Cytokinetics' and its partners' research and development activities of Cytokinetics' product candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to the risks related to Cytokinetics' business outlined in Cytokinetics' filings with the Securities and Exchange Commission particularly under the caption “Risk Factors” in Cytokinetics’ latest Annual Report on Form 10-K. Forward-looking statements are not guarantees of future performance, and Cytokinetics' actual results of operations, financial condition and liquidity, and the development of the industry in which it operates, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that Cytokinetics makes in this press release speak only as of the date of this press release. Cytokinetics assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release. CYTOKINETICS® and the CYTOKINETICS and C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries. Contact: Cytokinetics Diane Weiser Senior Vice President, Corporate Affairs (415) 290-7757HOUSTON (AP) — An elaborate parody appears to be behind an effort to resurrect Enron, the Houston-based energy company that exemplified the worst in American corporate fraud and greed after it went bankrupt in 2001. If its return is comedic, some former employees who lost everything in Enron’s collapse aren’t laughing. “It’s a pretty sick joke and it disparages the people that did work there. And why would you want to even bring it back up again?” said former Enron employee Diana Peters, who represented workers in the company’s bankruptcy proceedings. Here’s what to know about the history of Enron and the purported effort to bring it back. Once the nation’s seventh-largest company, Enron filed for bankruptcy protection on Dec. 2, 2001, after years of accounting tricks could no longer hide billions of dollars in debt or make failing ventures appear profitable. The energy company's collapse put more than 5,000 people out of work, wiped out more than $2 billion in employee pensions and rendered $60 billion in Enron stock worthless. Its aftershocks were felt throughout the energy sector. Twenty-four Enron executives , including former CEO Jeffrey Skilling , were eventually convicted for their roles in the fraud. Enron founder Ken Lay’s convictions were vacated after he died of heart disease following his 2006 trial. On Monday — the 23rd anniversary of the bankruptcy filing — a company representing itself as Enron announced in a news release that it was relaunching as a “company dedicated to solving the global energy crisis.” It also posted a video on social media, advertised on at least one Houston billboard and a took out a full-page ad in the Houston Chronicle In the minute-long video that was full of generic corporate jargon, the company talks about “growth” and “rebirth.” It ends with the words, “We’re back. Can we talk?” Enron's new website features a company store, where various items featuring the brand's tilted “E” logo are for sale, including a $118 hoodie. In an email, company spokesperson Will Chabot said the new Enron was not doing any interviews yet, but that "We’ll have more to share soon.” Signs point to the comeback being a joke. In the “terms of use and conditions of sale” on the company's website, it says “the information on the website about Enron is First Amendment protected parody, represents performance art, and is for entertainment purposes only.” Documents filed with the U.S. Patent and Trademark Office show that College Company, an Arkansas-based LLC, owns the Enron trademark. The co-founder of College Company is Connor Gaydos, who helped create a joke conspiracy theory that claims all birds are actually surveillance drones for the government. Peters said that since learning about the “relaunch” of Enron, she has spoken with several other former employees and they are also upset by it. She said the apparent stunt was “in poor taste.” “If it’s a joke, it’s rude, extremely rude. And I hope that they realize it and apologize to all of the Enron employees,” Peters said. Peters, who is 74 years old, said she is still working in information technology because “I lost everything in Enron, and so my Social Security doesn’t always take care of things I need done.” “Enron’s downfall taught us critical lessons about corporate ethics, accountability, and the consequences of unchecked ambition. Enron’s legacy was the employees in the trenches. Leave Enron buried,” she said. This story was corrected to fix the spelling of Ken Lay’s first name, which had been misspelled “Key.” Follow Juan A. Lozano on X at https://x.com/juanlozano70

Mike Harrington: Casey Mittelstadt's new chapter in Colorado is a work in progress

How to watch Las Vegas Raiders vs. Jacksonville Jaguars: TV channel, streaming info

Ruud van Nistelrooy enjoys winning start with Leicester

China's Huawei aims 100,000 apps on Harmony OS in 6-12 months

South Korea's leader prompts dismay by briefly declaring martial law. Here's what to know

Prime Minister Justin Trudeau is firmly in his Swiftie era. Trudeau attended the Taylor Swift concert in Toronto on Friday, the Eras Tour’s second-last night in the city. Press secretary Jenna Ghassabeh confirmed that the prime minister was at the concert with family members. Saturday wraps up two weekends of concerts in Toronto for the Eras Tour, which ends in Vancouver with three shows at BC Place from Dec. 6 to 8. The Eras Tour kicked off in March 2023 and touched down in five continents with nearly 150 performances. Before the Canadian dates were announced, Trudeau had reached out to Swift on social media, asking her to bring the tour to Canada.As we approach the end of December, the NBA MVP race has only intensified, with familiar faces continuing to dominate and new challengers emerging. In our previous rankings through November , Nikola Jokic held the top spot with his historic all-around brilliance, while stars like Shai Gilgeous-Alexander and Jayson Tatum followed closely behind, making strong cases of their own. Now, a month later, the field remains tightly contested as teams find their rhythm and players solidify their MVP narratives. This updated ranking highlights how the MVP race has evolved as we approach the New Year. 1. Nikola Jokic - Denver Nuggets (14-11) Season Stats: 31.0 PPG, 13.0 RPG, 9.8 APG, 1.8 SPG, 0.7 BPG, 3.8 TOV, 56.4% FG, 50.0% 3-PT FG, 80.3% FT Previous Ranking: 1st Nikola Jokic continues to redefine what dominance looks like in the modern NBA. His absurd combination of scoring, rebounding, and playmaking has kept the Nuggets afloat despite their middling record. Averaging a near triple-double with over 30 points per game, Jokic has been nothing short of masterful. What truly sets him apart is his efficiency—hitting 50% of his threes as a center while orchestrating the Nuggets' offense like a point guard. Denver's record needs to improve for him to secure his fourth MVP, but make no mistake, Jokic’s individual brilliance firmly places him in the driver's seat. 2. Shai Gilgeous-Alexander - Oklahoma City Thunder (22-5) Season Stats: 30.3 PPG, 5.5 RPG, 6.2 APG, 2.0 SPG, 1.0 BPG, 2.7 TOV, 50.8% FG, 33.5% 3-PT FG, 86.8% FT Previous Ranking: 2nd Shai Gilgeous-Alexander has elevated himself into superstardom and is powering the Thunder to one of the best records in the league. His two-way impact, marked by 30 points per game and elite defensive stats, has OKC looking like legitimate contenders. While his three-point shooting still leaves room for improvement, his ability to control the pace of the game and thrive in crunch time has made him indispensable. With the Thunder’s dominance in the Western Conference, SGA is right on Jokic’s tail when it comes to the MVP award, much like last season. Some might argue that his team record should give him the edge over Jokic and the point guard might end up being in the driver’s seat once the New Year rolls around because of that. Until things start to change considerably, Jokic is still the man to beat. 3. Giannis Antetokounmpo - Milwaukee Bucks (15-12) Season Stats: 32.7 PPG, 11.6 RPG, 6.0 APG, 0.7 SPG, 1.5 BPG, 3.4 TOV, 61.3% FG, 22.2% 3-PT FG, 61.4% FT Previous Ranking: 4th Giannis Antetokounmpo’s relentless energy and sheer physicality continue to overwhelm opponents, leading to yet another dominant statistical season as we all expected. However, the Bucks’ underwhelming record and his poor free-throw and three-point shooting percentages are blemishes on his campaign. Despite those setbacks, Giannis’ ability to dominate the paint and carry his team on both ends of the floor remains unmatched. The superstar forward was the difference in the Emiraes NBA Cup and we expect him to try to build on that. If Milwaukee can find more consistency, Giannis’ case will be impossible to ignore. 4. Jayson Tatum - Boston Celtics (22-6) Season Stats: 28.8 PPG, 9.3 RPG, 5.7 APG, 1.2 SPG, 0.5 BPG, 2.8 TOV, 46.3% FG, 37.2% 3-PT FG, 80.3% FT Previous Ranking: 3rd Jayson Tatum has been the embodiment of consistency for the Celtics , anchoring their stellar season with his scoring and rebounding prowess. His ability to elevate his teammates while delivering in clutch moments has been pivotal to Boston’s success. While his shooting efficiency is solid but not spectacular, Tatum’s all-around game and leadership shine through. As the Celtics remain atop the Eastern Conference, Tatum has positioned himself as a true MVP threat, capable of impacting the game in every facet. The only difference is that Jokic, SGA, and Giannis mean a little more to their teams than Tatum does, a testament to the Celtics’ tremendous talent pool. 5. Luka Doncic - Dallas Mavericks (18-10) Season Stats: 28.9 PPG, 8.6 RPG, 8.2 APG, 2.1 SPG, 0.5 BPG, 3.5 TOV, 45.9% FG, 35.5% 3-PT FG, 76.6% FT Previous Ranking: 8th Luka Doncic’s numbers this season highlight his brilliance. Averaging nearly 29 points, 9 rebounds, and 8 assists, Doncic continues to showcase his ability to control games with his scoring and playmaking. Dallas' strong start bolsters his MVP argument, though questions linger about his defensive impact and efficiency. Still, Luka’s ability to dominate offensively and make his teammates better solidifies his place among the league’s elite. The Mavericks are hell-bent on returning to the NBA Finals and depending on their performances so far, especially with Doncic leading the way, they look like a legitimate threat. 6. Karl-Anthony Towns - New York Knicks (18-10) Season Stats: 24.5 PPG, 14.0 RPG, 3.4 APG, 0.9 SPG, 1.0 BPG, 2.7 TOV, 53.0% FG, 45.9% 3-PT FG, 84.4% FT Previous Ranking: N/A Karl-Anthony Towns has thrived in his new home, becoming the centerpiece of a Knicks team that has a couple of talented star players. His double-double averages and incredible efficiency, particularly from deep, make him a unique weapon. While he’s not always the flashiest player, his impact on winning has been undeniable this season. Towns’ resurgence with the Knicks is one of the best storylines of the year, and he’s earned his spot in the MVP conversation without a doubt. The Timberwolves have definitely shot themselves in the foot with the trade this summer, and Towns has ultimately thrived in his current situation as the league’s leading rebounder. 7. Anthony Davis - Los Angeles Lakers (16-12) Season Stats: 26.9 PPG, 11.8 RPG, 3.4 APG, 1.3 SPG, 2.2 BPG, 2.3 TOV, 52.4% FG, 30.0% 3-PT FG, 78.1% FT Previous Ranking: 5th Anthony Davis is once again proving why he’s one of the most dominant big men in the league. His ability to anchor the defense while putting up 27 points per game is a testament to his two-way greatness. However, durability remains a looming concern, and his inconsistent three-point shooting limits his versatility. Still, with the Lakers performing well, Davis deserves recognition for his role in keeping them competitive. Credit has to go to JJ Redick for keeping the big man motivated to stay healthy and dominate the game like we know he can, and this could just be the start of Davis’ MVP campaign. 8. Victor Wembanyama - San Antonio Spurs (15-13) Season Stats: 24.7 PPG, 0.0 RPG, 3.9 APG, 1.1 SPGM 3.8 BPG, 3.5 TOV, 47.8% FG, 34.9% 3-PT FG, 87.5% FT Previous Ranking: N/A Victor Wembanyama’s second season has been nothing short of sensational. The Spurs phenom is averaging nearly 25 points with jaw-dropping defensive numbers, including a league-leading 3.8 blocks per game. His ability to impact the game on both ends at such a young age is astounding, and he’s already showing flashes of being the best two-way player in the world. If the Spurs can stay in the playoff hunt, Wemby’s MVP buzz will only grow louder and this is just the start. The team has some pretty talented players around the superstar center and that would mean the Spurs could look forward to many more seasons of record above .500. 9. Trae Young - Atlanta Hawks (14-15) Season Stats: 21.6 PPG, 3.9 RPG, 12.2 APG, 1.3 SPG, 0.1 BPG, 4.6 TOV, 39.0% FG, 32.0% 3-PT FG, 88.1% FT Previous Ranking: N/A Trae Young’s season has been a mixed bag. While his playmaking is elite, leading the league in assists, his scoring efficiency is abysmal, with career-low shooting percentages. The Hawks’ struggles as a team also don’t help his case, but the difference has been the point guard’s tremendous clutch performances. Young’s ability to create offense for himself and his teammates keeps him in the conversation, and his MVP stock is a direct representation of that. The Hawks are finding some excellent performances from Jalen Johnson and De’Andre Hunter but Young is the undisputed star of the team and the team goes as he goes. 10. Donovan Mitchell - Cleveland Cavaliers (25-4) Season Stats: 23.3 PPG, 4.7 RPG, 4.5 APG, 1.6 SPG, 0.3 BPG, 2.1 TOV, 45.2% FG, 40.5% 3-PT FG, 79.8% FT Previous Ranking: 6th Donovan Mitchell continues to be the driving force behind the Cavaliers’ incredible start, leading the team with his scoring and timely defense. While his raw numbers may not pop compared to others on this list, his efficiency and ability to take over games in key moments make him invaluable. With the Cavaliers boasting the best record in the league, Mitchell’s impact on winning cannot be overstated, keeping him firmly in the MVP race although credit has to be given to star Evan Mobley who is finally realizing his potential as a two-way big man. This article first appeared on Fadeaway World and was syndicated with permission.